866-997-4948(US-Canada Toll Free)

Hyperlipidemia - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Apr 2014

Category :

Metabolic Disorders

No. of Pages : 147 Pages

Hyperlipidemia Pipeline Review, H1 2014, provides an overview of the Hyperlipidemias therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hyperlipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperlipidemia and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hyperlipidemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Hyperlipidemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Hyperlipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hyperlipidemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hyperlipidemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hyperlipidemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content

Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Hyperlipidemia Overview 11
Therapeutics Development 12
Pipeline Products for Hyperlipidemia - Overview 12
Pipeline Products for Hyperlipidemia - Comparative Analysis 13
Hyperlipidemia - Therapeutics under Development by Companies 14
Hyperlipidemia - Therapeutics under Investigation by Universities/Institutes 17
Hyperlipidemia - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Hyperlipidemia - Products under Development by Companies 22
Hyperlipidemia - Products under Investigation by Universities/Institutes 25
Hyperlipidemia - Companies Involved in Therapeutics Development 26
Amgen Inc. 26
Eli Lilly and Company 27
Isis Pharmaceuticals, Inc. 28
Daewoong Pharmaceutical Co., Ltd. 29
Dr. Reddy\'s Laboratories Limited 30
Pfizer Inc. 31
Idera Pharmaceuticals, Inc. 32
Alnylam Pharmaceuticals, Inc. 33
Yuhan Corporation 34
Regeneron Pharmaceuticals, Inc. 35
HanAll Biopharma Co., Ltd. 36
Ahn-Gook Pharmaceutical Co., Ltd. 37
LG Life Sciences, Ltd. 38
CJ CheilJedang Corp. 39
Catabasis Pharmaceuticals, Inc. 40
aRigen Pharmaceuticals, Inc. 41
Zhejiang Hisun Pharmaceutical Co., Ltd. 42
miRagen Therapeutics, Inc. 43
Esperion Therapeutics, Inc. 44
Pharmena SA 45
FORMAC Pharmaceuticals N.V. 46
Hanmi Pharmaceuticals, Co. Ltd. 47
Michigan Life Therapeutics, LLC 48
BCWorld Pharm Co. Ltd. 49
Hyperlipidemia - Therapeutics Assessment 50
Assessment by Monotherapy Products 50
Assessment by Combination Products 51
Assessment by Target 52
Assessment by Mechanism of Action 56
Assessment by Route of Administration 60
Assessment by Molecule Type 62
Drug Profiles 64
(atorvastatin calcium + losartan potassium) - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
(rosuvastatin + telmisartan) - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
evolocumab - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
bococizumab - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
(irbesartan + atorvastatin calcium) - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
(rosuvastatin calcium + olmesartan medoxomil) - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
(rosuvastatin + valsartan) - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
IMD-4 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Coenzyme A - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
DRL-17822 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
TRIA-662 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
ETC-1002 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
gemcabene calcium - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
CAT-2003 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
(simvastatin + losartan potassium) - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
(simvastatin Immediate Release + amlodipine maleate Delayed Release) - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
LY-3015014 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
HCP-1007 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
AGSAA-010 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
fenofibrate - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
(rosuvastatin + amlodipine) - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
(atorvastatin calcium + metformin) - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
(rosuvastatin + metformin) - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
(gemigliptin + statin) - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
BCWP-C-001 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
PF-06678552 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
ISIS-ANGPTL3 Rx - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
HS-25 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
IMO-3100 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
ARMAK-105 - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
JCH-2 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
CideB Antisense Oligonucleotide - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
cSN-50 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Drug Targeting TRIP-Br2 for Metabolic Disorders - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
REGN-1001 - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
S-0101870 - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
BSN-272 - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
ALN-ANG - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
CSN-501 - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
Drugs For Cardivascular Disease - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
Small Molecule for Cardiovascular And Metabolic Disorders - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
N-11 - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
DWJ-1330 - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
Hyperlipidemia - Recent Pipeline Updates 113
Hyperlipidemia - Dormant Projects 132
Hyperlipidemia - Discontinued Products 136
Hyperlipidemia - Product Development Milestones 137
Featured News & Press Releases 137
Mar 30, 2014: Data From Phase 3 Pivotal Studies Show Amgen\'s Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On Statins 137
Mar 19, 2014: Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-ANGPTL3 Rx to Treat Hyperlipidemia 140
Mar 05, 2014: Esperion Therapeutics Provides ETC-1002 Program Update 140
Jul 02, 2013: Mylan Gets FDA Tentative Approval For Rosuvastatin Calcium Tablets 140
Apr 05, 2013: Hanmi Pharma Receives Korean Patent For Its Technology In Ibestin 141
Mar 09, 2013: Merck Announces Presentation Of Results From HPS2-THRIVE Study Of Tredaptive At 62nd American College Of Cardiology Scientific Sessions 141
Feb 26, 2013: Merck\'s Niacin-Statin Combination Significantly Increases Adverse Side-effects, Phase III Study Shows 142
Jan 15, 2013: Mochida Pharma Announces Phase II Results Of Epadel For Treatment Of Hyperlipidemia And Arteriosclerosis Obliterans 143
Jan 11, 2013: MSD Provides Update On Next Steps For Tredaptive 143
Jan 10, 2013: Pronova Biopharma And Takeda Announce Availability Of Lotriga In Japan 144

Appendix 146
Methodology 146
Coverage 146
Secondary Research 146
Primary Research 146
Expert Panel Validation 146
Contact Us 147
Disclaimer 147

List of Table


Number of Products under Development for Hyperlipidemia, H1 2014 12
Number of Products under Development for Hyperlipidemia - Comparative Analysis, H1 2014 13
Number of Products under Development by Companies, H1 2014 15
Number of Products under Development by Companies, H1 2014 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2014 18
Comparative Analysis by Late Stage Development, H1 2014 19
Comparative Analysis by Clinical Stage Development, H1 2014 20
Comparative Analysis by Early Stage Development, H1 2014 21
Products under Development by Companies, H1 2014 22
Products under Development by Companies, H1 2014 (Contd..1) 23
Products under Development by Companies, H1 2014 (Contd..2) 24
Products under Investigation by Universities/Institutes, H1 2014 25
Hyperlipidemia - Pipeline by Amgen Inc., H1 2014 26
Hyperlipidemia - Pipeline by Eli Lilly and Company, H1 2014 27
Hyperlipidemia - Pipeline by Isis Pharmaceuticals, Inc., H1 2014 28
Hyperlipidemia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2014 29
Hyperlipidemia - Pipeline by Dr. Reddy\'s Laboratories Limited, H1 2014 30
Hyperlipidemia - Pipeline by Pfizer Inc., H1 2014 31
Hyperlipidemia - Pipeline by Idera Pharmaceuticals, Inc., H1 2014 32
Hyperlipidemia - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2014 33
Hyperlipidemia - Pipeline by Yuhan Corporation, H1 2014 34
Hyperlipidemia - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2014 35
Hyperlipidemia - Pipeline by HanAll Biopharma Co., Ltd., H1 2014 36
Hyperlipidemia - Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H1 2014 37
Hyperlipidemia - Pipeline by LG Life Sciences, Ltd., H1 2014 38
Hyperlipidemia - Pipeline by CJ CheilJedang Corp., H1 2014 39
Hyperlipidemia - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2014 40
Hyperlipidemia - Pipeline by aRigen Pharmaceuticals, Inc., H1 2014 41
Hyperlipidemia - Pipeline by Zhejiang Hisun Pharmaceutical Co., Ltd., H1 2014 42
Hyperlipidemia - Pipeline by miRagen Therapeutics, Inc., H1 2014 43
Hyperlipidemia - Pipeline by Esperion Therapeutics, Inc., H1 2014 44
Hyperlipidemia - Pipeline by Pharmena SA, H1 2014 45
Hyperlipidemia - Pipeline by FORMAC Pharmaceuticals N.V., H1 2014 46
Hyperlipidemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2014 47
Hyperlipidemia - Pipeline by Michigan Life Therapeutics, LLC, H1 2014 48
Hyperlipidemia - Pipeline by BCWorld Pharm Co. Ltd., H1 2014 49
Assessment by Monotherapy Products, H1 2014 50
Assessment by Combination Products, H1 2014 51
Number of Products by Stage and Target, H1 2014 54
Number of Products by Stage and Mechanism of Action, H1 2014 58
Number of Products by Stage and Route of Administration, H1 2014 61
Number of Products by Stage and Molecule Type, H1 2014 63
Hyperlipidemia Therapeutics - Recent Pipeline Updates, H1 2014 113
Hyperlipidemia - Dormant Projects, H1 2014 132
Hyperlipidemia - Dormant Projects (Contd..1), H1 2014 133
Hyperlipidemia - Dormant Projects (Contd..2), H1 2014 134
Hyperlipidemia - Dormant Projects (Contd..3), H1 2014 135
Hyperlipidemia - Discontinued Products, H1 2014 136

List of Chart


Number of Products under Development for Hyperlipidemia, H1 2014 12
Number of Products under Development for Hyperlipidemia - Comparative Analysis, H1 2014 13
Number of Products under Development by Companies, H1 2014 14
Number of Products under Investigation by Universities/Institutes, H1 2014 17
Comparative Analysis by Clinical Stage Development, H1 2014 20
Comparative Analysis by Early Stage Products, H1 2014 21
Assessment by Monotherapy Products, H1 2014 50
Assessment by Combination Products, H1 2014 51
Number of Products by Top 10 Target, H1 2014 52
Number of Products by Stage and Top 10 Target, H1 2014 53
Number of Products by Top 10 Mechanism of Action, H1 2014 56
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 57
Number of Products by Top 10 Route of Administration, H1 2014 60
Number of Products by Stage and Top 10 Route of Administration, H1 2014 61
Number of Products by Top 10 Molecule Type, H1 2014 62
Number of Products by Stage and Top 10 Molecule Type, H1 2014 63

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *